Add like
Add dislike
Add to saved papers

Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings.

Treatment for keloids remains less than ideal. Previous discouraging results prompted a change in the author's standard treatment for keloids to surgery plus adjuvant intralesional verapamil and pressure earrings. Intralesional verapamil (2.5 mg per milliliter) was administered 7 to 14 days after keloid removal and again approximately 1 month after removal when possible. Between 0.5 ml and 2.0 ml was administered each time, depending on the size of the keloid. Patients were instructed to wear pressure earrings essentially continuously for a minimum of 6 months after excision. Thirty-five African American patients with 45 earlobe keloids were treated with this regimen. Information regarding recurrence was obtained by follow-up, mail, or phone call from 31 patients (89%) with 40 keloids (89%). Minimum follow-up for inclusion was 6 months and average follow-up was 28 months. Twenty-two keloids (55%) in 16 patients (52%) were cured by this treatment modality. There were no significant differences in recurrence rates related to sex, age, keloid size, length of time the keloid was present, how long the ears had been pierced, and how many verapamil injections were received. There was a trend toward an increased recurrence rate for previously treated keloids. Though not optimal, this regimen is superior to some previously evaluated regimens.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app